Abstract The invention provides novel antibiotic compounds which are 7β-acylamidoceph-3-em-4-carboxylic acids, and non-toxic derivatives thereof characterized in that the acylamido group has the structure ##STR1## WHERE R is a hydrogen atom or an organic group and R a is an etherifying monovalent organic group linked to the oxygen atom through a carbon atom. The compounds are syn isomers or exist as mixtures containing at least 75% of the syn isomer. These antibiotic compounds possess high antibacterial activity against a range or gram positive and gram negative organisms coupled with particularly high stability to β-lactamases produced by various gram negative organisms. The invention is also concerned with the administration of the compounds.
A compound selected from the group consisting of a highly active cephalosporin antibiotic highly stable to β-lactamases of the formula ##STR153## wherein R u is thienyl or furyl; R b is lower alkyl; lower alkyl substituted by lower alkoxy, amino or bromo; or unsubstituted C 3-7 cycloalkyl; and R d is H or carbamoyl, said cephalosporin antibiotic being in the form of a syn-isomer free of the corresponding anti-isomer to the extent of at least 75% based on the total weight of said antibiotic; and a physiologically acceptable salt thereof.
Claim 2
Dependent Claim
90 words
A compound selected from the group consisting of a highly active cephalosporin antibiotic highly stable to β-lactamases of the formula ##STR153## wherein R u is thienyl or furyl; R b is lower alkyl; lower alkyl substituted by lower alkoxy, amino or bromo; or unsubstituted C 3-7 cycloalkyl; and R d is H or carbamoyl, said cephalosporin antibiotic being in the form of a syn-isomer free of the corresponding anti-isomer to the extent of at least 75% based on the total weight of said antibiotic; and a physiologically acceptable salt thereof.